A trial is reported of sustained-release quinidine bisulphate (Kinidin Durules) controlled by quinidine blood levels used to maintain sinus rhythm after the electroversion of atrial dysrhythmias in 24 patients. Sinus rhythm was brought about by phased direct current shock, neither preceded by nor followed by Kinidin, and all 24 patients relapsed to their original rhythm disturbance, the mean relapse time being 3-75 months after DC shock. A second electroversion preceded and followed by maintenance Kinidin was performed, and the mean electrical energy for conversion to sinus rhythm remained unchanged at 142joules. The dose of slow-release quinidine was controlled by frequent quinidine blood levels. A careful follow-up study was maintained for 26 months.
while in selected patients in whom the drug is well tolerated, particularly if relapse to atrial fibrillation or flutter has occurred within the first few months after electroversion and in whom sinus rhythm is haemodynamically important.
Synchronized capacitor discharge is more effective than alternating current in treating ventricular dysrhythmias (Lown, Amarasingham, and Neuman, I962) and more effective than drug therapy in converting supraventricular rhythm disturbances to sinus rhythm (McDonald, Resnekov, and O'Brien, I964) . Though initially considered a benign form of treatment (Lown, I964; Morris et al., 1964) , potentially serious complications were soon reported (McDonald and Resnekov, i965) , and an incidence of I4'5 per cent complications was documented in a consecutive series of 220 patients treated (Resnekov and McDonald, I967) . In addition, the number of patients remaining in sinus rhythm after successful electroversion may be disappointingly small. By 9j months after treatment, 50 per cent of I93 patients being followed had reverted to their original dysrhythmia (Resnekov and McDonald, I968) , nor did quinidine in a divided total dosage of i '2 g. daily appear helpful in maintaining sinus rhythm in these patients. In this communication we wish to report a study in which a new form of sustained-release quinidine -Kinidin Durule (Sannerstedt, I960; Sjogren, I959; Sjogren and Fryklof, I960 ; Sjogren and Ostholm, I96I) was used estimations in an attempt to maintain sinus rhythm after electroversion. Each patient acted as his own control.
Patients
Twenty-four patients were studied, all of whom had initially responded to DC shock but who had then relapsed to their original dysrhythmia. Atrial fibrillation was the presenting rhythm in i8, atrial flutter in 5, and paroxysmal atrial tachycardia in i (Table i) . Rheumatic valvar heart disease was present in ii, coronary heart disease in 4, cardiomyopathy in 2, congenital heart disease (postoperative atrial septal defect) in i, and no underlying heart disease could be detected in 6.
Method
Patients were treated with direct current shock as previously described (McDonald et (Resnekov, I965) . In addition, parasympathetic and sympathetic +mediators released at the time of DC shock may be important in an abrupt return of the initial rhythm disturbance (Childers, Rothbaum, and Arnsdorf, I967) .
Quinidine therapy has been considered the ,treatment of choice for maintaining sinus rhythm in patients with chronic atrial fibrillastion after successful DC shock (Lown, Kleiger, and Wolff, I964 Kinidin Durules are tablets of quinidine bisulphate in which the active drug is embedded in a porous insoluble plastic tablet. It releases 40 per cent of the dose in the first hour and the remainder is steadily released over the next 8 hours. Quinidine is probably not absorbed in the stomach, but is rapidly absorbed in the alkaline medium of the small intestine. Using Kinidin Durules, the maximum concentration achieved is significantly lower and the peak quinidine concentration seen after the ordinary form of quinidine bisulphate is replaced by a plateau which develops gradually and then falls off (Fig. i) . The absence of fluctuations of concentration indicate that the release is regular and also reliable in respect to different patients. The elimination of Kinidin appears to be similar to the elimination of quinidine sulphate. Therapeutically effective levels of plasma or serum concentration, however, can be easily achieved using this new preparation and can be maintained for a prolonged period of time. In our series, the maximum concentration appeared 2 to 4 hours after the initial dose (Fig. i) , and there was little difficulty in maintaining patients in the therapeutic range.
It is important to consider the method of quinidine estimation. Two methods are commonly used, namely that of Cramer and Isaksson (I963), and that of Hamfelt and Malers (I963) . Throughout the trial, both were used and compared. The method of Cramer and Isaksson is an extraction one based on the methods proposed by Brodie, Udenfriend, and Baer (I947a) and by Brodie et al. (1947b) Despite the absence of peaking of serum quinidine levels, the incidence of complications in our series was disappointingly high, and as already described the drug had to be stopped in two patients because of uncontrollable symptoms.
The factors important in maintaining sinus rhythm are the length of time the dysrhythmia has been present before treatment, the overall size of the heart, the size of the left atrium, the underlying heart condition, and the integrity of the sinus mechanism (Resnekov, 1965) , and slow-release quinidine sulphate does not appear to be beneficial when any or all of these are unfavourable. In contrast to the results published by Sokolow and Perloff (I960-6i), our results were not influenced by the underlying heart condition, though as can be seen from 
